Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ketone drink may boost brain fuel in prediabetes

NCT ID NCT07546409

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at whether older adults with prediabetes have lower brain energy use and slower thinking compared to those with normal blood sugar. It also tests if a single dose of a ketone supplement can improve brain energy and processing speed. Twenty participants will undergo brain scans and cognitive tests before and after taking the supplement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ketone monoester supplement (DeltaG)
What this could lead to
If it works, this could point toward a nutritional strategy to support brain function in people at risk for dementia.
What could go wrong
This is a very small, early study (20 people) testing only a single dose. Results may not apply to long-term use or to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 60 to 75 years * Able to provide written informed consent * Fluent in English * No diagnosed cognitive impairment or dementia Classified as either: * Prediabetes (based on American Diabetes Association criteria), or Normal glucose regulation (control group) * Medically stable and cleared to undergo positron emission tomography and magnetic resonance imaging * Willing to comply with study procedures, including metabolic testing, supplement ingestion, and neuroimaging Exclusion Criteria: * Diagnosis of mild cognitive impairment, dementia, or other neurodegenerative disorder * Diagnosis of type 1 diabetes or type 2 diabetes * Use of glucose-lowering medications (e.g., insulin, metformin, glucagon-like peptide-1 receptor agonists) * History of major neurological disorder (e.g., stroke, traumatic brain injury with loss of consciousness \>30 minutes, epilepsy, multiple sclerosis) * Major psychiatric disorder not stable on treatment * Uncontrolled hypertension or significant cardiovascular disease * Severe renal, hepatic, or gastrointestinal disease that may affect supplement metabolism * Contraindications to magnetic resonance imaging (e.g., non-compatible implanted devices, severe claustrophobia)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy controls are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UAB Comprehensive Cancer Center

    RECRUITING

    Birmingham, Alabama, 35205, United States

  • Webb Nutrition Sciences Building

    RECRUITING

    Birmingham, Alabama, 35205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.